Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group (Journal article)

Fountzilas, G./ Papadimitriou, C./ Dafni, U./ Bafaloukos, D./ Skarlos, D./ Moulopoulos, L. A./ Razis, E./ Kalofonos, H. P./ Aravantinos, G./ Briassoulis, E./ Papakostas, P./ Abela, K./ Gogas, E./ Kosmidis, P./ Pavlidis, N./ Dimopoulos, M. A.

PURPOSE: To compare the efficacy of two different schedules of epirubicin and paclitaxel, as first-line chemotherapy, in patients with advanced breast cancer (ABC). PATIENTS AND METHODS: From October 1997 until May 1999, 183 eligible patients with ABC entered the study. Chemotherapy in group A (93 patients) consisted of four cycles of epirubicin at a dose of 110 mg/m(2) followed by four cycles of paclitaxel at a dose of 225 mg/m(2) in a 3-hour infusion. All cycles were repeated every 2 weeks with granulocyte colony-stimulating factor support. The therapeutic regimen in group B (90 patients) consisted of epirubicin (80 mg/m(2)) immediately followed by paclitaxel (175 mg/m(2) in a 3-hour infusion) every 3 weeks for six cycles. RESULTS: In total, 79 patients (85%) in group A and 72 patients (80%) in group B completed treatment. The median relative dose-intensity of epirubicin was 0.96 in both groups, and that of paclitaxel was 0.96 and 0.97 in groups A and B, respectively. The complete response rate was higher in group A (21.5% v 9% P =.02). Nevertheless, there was no significant difference in the overall response rate between the two groups (55% v 42%, P =.10). Severe neutropenia was more frequently observed with concurrent treatment. After a median follow-up of 16.5 months, median time to progression was 10 months in group A and 8.5 months in group B (P =.27), and median survival was 21.5 and 20 months, respectively (P =.17). CONCLUSION: The present study failed to demonstrate a significant difference in overall response rate between dose-dense sequential administration of epirubicin and paclitaxel compared with the combination of the two drugs given on the same day, even though the sequential treatment resulted in a significantly higher complete response rate.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Adult,Aged,Antineoplastic Combined Chemotherapy Protocols/*therapeutic use,Breast Neoplasms/*drug therapy/pathology,Disease Progression,Dose-Response Relationship, Drug,Drug Administration Schedule,Epirubicin/administration & dosage,Female,Granulocyte Colony-Stimulating Factor/administration & dosage,Humans,Male,Middle Aged,Neutropenia/chemically induced,Paclitaxel/administration & dosage,Survival Analysis,Treatment Outcome
URI: https://olympias.lib.uoi.gr/jspui/handle/123456789/22354
ISSN: 0732-183X
Link: http://www.ncbi.nlm.nih.gov/pubmed/11304776
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Pavlidis-2001-dose dense sequential.pdf85.7 kBAdobe PDFView/Open


 Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22354
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.